The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InEvernorth Behavioral Health, a division of the Cigna Group, has announced the removal of prior authorization requirements for Transcranial Magnetic Stimulation (TMS) therapy. This strategic policy change is set to take effect on March 6, 2026, and will cover more than 18 million beneficiaries across 12 states. BrainsWay, a global leader in noninvasive brain stimulation technologies, stands to benefit significantly from this reduction in administrative hurdles. The move aims to streamline access to mental health care and accelerate the time between clinical diagnosis and the commencement of treatment. Analysts view this development as a major bullish catalyst for BrainsWay, as it facilitates broader market penetration in the U.S. healthcare sector. By eliminating insurance barriers, the company is expected to see a substantial increase in the adoption of its advanced medical technology and overall revenue growth.